Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.51 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465277 | 0.95 | NCF1 (0.56) | NCF1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL7981893 | 0.90 | GAA (0.56) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL28312975 | 0.90 | SMARCA2 (0.49) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL615074 | 0.88 | CHRM2 (0.52) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL28708137 | 0.86 | GPR119 (0.49) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL7986047 | 0.85 | CKS1B (0.57) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL615082 | 0.85 | GPR119 (0.48) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL8567338 | 0.85 | GPR119 (0.48) | SMARCA2SMARCA4PBRM1GPR119GAA | |
| SCHEMBL2459105 | 0.85 | GPR119 (0.45) | NCF1GPR119NAMPTMC4R | |
| SCHEMBL4511470 | 0.84 | GPR119 (0.50) | SMARCA2SMARCA4PBRM1GPR119GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2023125476-A1 | SPIRO COMPOUND, AND BIFUNCTIONAL COMPOUND AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3805218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| US-5885999-A | TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 1999-03-23 | — | — | US | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0783498-A4 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO INC (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0783498-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5607936-A | USEFUL IN TREATMENT OF RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996010568-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | NCF1 1990/4885SMARCA2 4437/4885SMARCA4 4290/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885SMARCA2 4193/4885SMARCA4 2868/4885 |
| US-20210276988-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885SMARCA2 4193/4885SMARCA4 2868/4885 |
| US-20210107912-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NCF1 1206/4885SMARCA2 2248/4885SMARCA4 1814/4885 |
| US-20210221814-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | NCF1 1206/4885SMARCA2 2248/4885SMARCA4 1814/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | NCF1 3000/4885SMARCA2 2775/4885SMARCA4 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.